L Boccon-Gibod

The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

Laurence Klotz, L Boccon-Gibod, Neal D. Shore et al. · British Journal of Urology · 2008 · 614 citations · Full text

Medicine, Oncology, Pharmacology +17

PROSPECTIVE EVALUATION OF PROSTATE CANCER DETECTED ON BIOPSIES 1, 2, 3 AND 4: WHEN SHOULD WE STOP?

Bob Djavan, V. Ravery, A. Zlotta et al. · The Journal of Urology · 2001 · 448 citations

Medicine, Oncology, Urology +17

EXTENSIVE BIOPSY PROTOCOL IMPROVES THE DETECTION RATE OF PROSTATE CANCER

V. Ravery, LAURENT GOLDBLATT, Benoît Royer et al. · The Journal of Urology · 2000 · 160 citations

Medicine, Oncology, Urology +10

A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

E. David Crawford, Bertrand Tombal, Kurt Miller et al. · The Journal of Urology · 2011 · 153 citations

Medicine, Oncology, Pharmacology +16

Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

Bertrand Tombal, Kurt Miller, L Boccon-Gibod et al. · European Urology · 2009 · 147 citations

Medicine, Oncology, Pharmacology +8